The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies

Clinics in Dermatology

Volumn 28, Issue 1, 2010, Pages 24-30

  Rigopoulos, Dimitris ^a   Larios, George ^a   Katsambas, Andreas D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; EMOLLIENT AGENT; ETHINYLESTRADIOL; HYPERICUM PERFORATUM EXTRACT; ISOTRETINOIN; LIPID; LOW DOSE ORAL CONTRACEPTIVE; NORETHISTERONE; PHENYTOIN; PROGESTERONE; RETINOL; TETRACYCLINE;

ACNE; ACNE CONGLOBATA; ACNE FULMINANS; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; COMEDO; CORNEA OPACITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRY EYE; DRY NOSE; DRY SKIN; ENTERITIS; FOLLICULITIS; FOOD; FOOD DRUG INTERACTION; HEPATITIS; HUMAN; HYPEROSTOSIS; IMMUNOMODULATION; INTRACRANIAL HYPERTENSION; KERATINIZATION; LIPOGENESIS; LOW DRUG DOSE; MENTAL STRESS; MYALGIA; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PRURITUS; RECURRENT DISEASE; REMISSION; RETINOL INTOXICATION; SCAR FORMATION; SEBORRHEA; SEBUM SECRETION; SIDE EFFECT; SKIN EXFOLIATION; SKIN INFLAMMATION; SKIN MANIFESTATION; TERATOGENICITY; TREATMENT DURATION; VISUAL DISORDER; XEROSTOMIA;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; ISOTRETINOIN; MAXIMUM TOLERATED DOSE; MENTAL DISORDERS; PATIENT EDUCATION AS TOPIC; PRODUCT LABELING; RECURRENCE; SEVERITY OF ILLNESS INDEX; STOMATITIS; UNITED STATES; VISION DISORDERS;

EID: 71849096438     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.03.005     Document Type: Article

References (88)

1. Cunliffe W.J., and Gould D.J. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J 1 (1979) 1109-1110
2. Dreno B., and Poli F. Epidemiology of acne. Dermatology 206 (2003) 7-103
3. Stathakis V., Kilkenny M., and Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol 38 (1997) 115-234
4. Burton J.L., Cunliffe W.J., Stafford I., and Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol 85 (1971) 119-126
5. White G.M. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 39 (1998) S34-S37
6. Thomas D.R. Psychosocial effects of acne. J Cutan Med Surg 8 suppl 4 (2004) 3-5
7. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol 32 (1995) S26-S30
8. Fried R.G., and Wechsler A. Psychological problems in the acne patient. Dermatol Ther 19 (2006) 237-240
9. Brown S.K., and Shalita A.R. Acne vulgaris. Lancet 351 (1998 20) 1871-1876
10. Haider A., and Shaw J.C. Treatment of acne vulgaris. JAMA. 292 (2004) 726-735
11. Webster G.F. Acne vulgaris. BMJ 325 (2002) 475-479
12. Gollnick H., Cunliffe W., Berson D., et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 49 1 suppl (2003) S1-S37
13. Zouboulis C.C., Schagen S., and Alestas T. The sebocyte culture: a model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhoea and acne. Arch Dermatol Res 300 (2008) 397-413
14. Böhm M., and Luger T.A. The pilosebaceous unit is part of the skin immune system. Dermatology 196 (1998) 75-79
15. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol 15 suppl 3 (2001) 43-49
16. Zouboulis C.C. Acne and sebaceous gland function. Clin Dermatol 22 (2004) 360-366
17. Zouboulis C.C., Eady A., Philpott M., et al. What is the pathogenesis of acne?. Exp Dermatol 14 (2005) 143-152
18. Jeremy A.H., Holland D.B., Roberts S.G., Thomson K.F., and Cunliffe W.J. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 121 (2003) 20-27
19. Usatine R.P., and Quan M.A. Pearls in the management of acne: an advanced approach. Prim Care 27 (2000) 289-308
20. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs 5 (2003) 301-313
21. Burkhart C.N., and Gottwald L. Assessment of etiologic agents in acne pathogenesis. Skinmed 2 (2003) 222-228
22. Karvonen S.L., Räsänen L., Cunliffe W.J., Holland K.T., Karvonen J., and Reunala T. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. Dermatology 189 (1994) 344-349
23. Jugeau S., Tenaud I., Knol A.C., et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 153 (2005) 1105-1113
24. Katsambas A.D., Stefanaki C., and Cunliffe W.J. Guidelines for treating acne. Clin Dermatol 22 (2004) 439-444
25. Hayashi N., Suh D.H., Akamatsu H., Kawashima M., and Acne Study Group. Evaluation of the newly established acne severity classification among Japanese and Korean dermatologists. J Dermatol 35 (2008) 261-263
26. Cook C.H., Centner R.L., and Michaels S.E. An acne grading method using photographic standards. Arch Dermatol 115 (1979) 571-575
27. Feldman S., Careccia R.E., Barham K.L., and Hancox J. Diagnosis and treatment of acne. Am Fam Physician 69 (2004) 2123-2130
28. Pochi P.E., Shalita A.R., Strauss J.S., et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 24 (1991) 495-500
29. Karvonen S.L. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 28 (1993) 572-579
30. Seukeran D.C., and Cunliffe W.J. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 141 (1999) 307-309
31. Jansen T., Grabbe S., and Plewig G. [Clinical variants of acne]. Hautarzt 56 (2005) 1018-1026
32. Harper J.C., and Thiboutot D.M. Pathogenesis of acne: recent research advances. Adv Dermatol 19 (2003) 1-10
33. Katsambas A., and Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther 21 (2008) 86-95
34. Geiger J.M., Hommel L., Harms M., and Saurat J.H. Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J Am Acad Dermatol 34 (1996) 513-515
35. Zouboulis C.C. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 126 (2006) 2154-2156
36. Nelson A.M., Gilliland K.L., Cong Z., and Thiboutot D.M. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 126 (2006) 2178-2189
37. Cooper A.J., and Australian Roaccutane Advisory Board. Treatment of acne with isotretinoin: recommendations based on Australian experience. Australas J Dermatol 44 (2003) 97-105
38. Coates P., Adams C.A., Cunliffe W.J., et al. Does oral isotretinoin prevent Propionibacterium acnes resistance?. Dermatology 195 suppl 1 (1997) 4-9 [discussion 38-40]
39. Coates P., Vyakrnam S., Ravenscroft J.C., et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol 153 (2005) 1126-1136 Erratum inBr J Dermatol 2006 154807
40. Wozel G., Chang A., Zultak M., et al. The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res 28 (1991) 158-161
41. Papakonstantinou E., Aletras A.J., Glass E., et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 125 (2005) 673-684
42. Accutane (isotretinoin) capsules: complete product information [package insert] (2007), Roche Laboratories, Nutley (NJ)
43. Layton A.M., Dreno B., Gollnick H.P., and Zouboulis C.C. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 20 (2006) 773-776
44. Dréno B., Bettoli V., Ochsendorf F., et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 16 (2006) 565-571
45. Böni R., and Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 4 (2003) 273-276
46. Neubert U., Plewig G., and Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 278 (1986) 307-313
47. Colburn W.A., Gibson D.M., Wiens R.E., and Hanigan J.J. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 23 (1983) 534-539
48. Ghaffarpour G., Mazloomi S., Soltani-Arabshahi R., and Seyed K.S. Oral isotretinoin for acne, adjusting treatment according to patient's response. J Drugs Dermatol 5 (2006) 878-882
49. Thielitz A., Krautheim A., and Gollnick H. Update in retinoid therapy of acne. Dermatol Ther 19 (2006) 272-279
50. Layton A.M., and Cunliffe W.J. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 27 (1992) S2-S7
51. Orfanos C.E., and Zouboulis C.C. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 196 (1998) 140-147
52. Layton A.M., Knaggs H., Taylor J., and Cunliffe W.J. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol 129 (1993) 292-296
53. Katsambas A., and Papakonstantinou A. Acne: systemic treatment. Clin Dermatol 22 (2004) 412-418
54. Cunliffe W.J., van de Kerkhof P.C., Caputo R., et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 194 (1997) 351-357
55. Harms M. Isotretinoin: 10 years on. Dermatology 186 (1993) 81-82
56. Hermes B., Praetel C., and Henz B.M. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol 11 (1998) 117-121
57. Lehucher-Ceyrac D., and Weber-Buisset M.J. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 186 (1993) 123-128
58. Goulden V., Clark S.M., McGeown C., and Cunliffe W.J. Treatment of acne with intermittent isotretinoin. Br J Dermatol 137 (1997) 106-108
59. Kaymak Y., and Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol 20 (2006) 1256-1260
60. Amichai B., Shemer A., and Grunwald M.H. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 54 (2006) 644-646
61. Mandekou-Lefaki I., Delli F., Teknetzis A., Euthimiadou R., and Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 23 (2003) 41-46
62. Geissler S.E., Michelsen S., and Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 1 (2003) 952-958
63. Kuenzli S., and Saurat J.H. Retinoids. In: Bolognia J.L., Jorizzo J.L., and Rapini R.P. (Eds). Dermatology e-dition. 2nd ed. (2008), Mosby Elsevier, London (UK)
64. Ortonne J.P. Oral isotretinoin treatment policy. Do we all agree?. Dermatology 195 suppl 1 (1997) 34-37 [discussion 38-40]
65. Harms M., Masouyé I., and Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 172 (1986) 148-153
66. Stainforth J.M., Layton A.M., Taylor J.P., and Cunliffe W.J. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?. Br J Dermatol 129 (1993) 297-301
67. Leyden J.J. Oral isotretinoin. How can we treat difficult acne patients?. Dermatology 195 suppl 1 (1997) 29-33 discussion 38-40
68. [No authors listed]. Safe use of acne drug. FDA Consum 39 (2005) 4
69. Ellis C.N., and Krach K.J. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45 (2001) S150-S157
70. David M., Hodak E., and Lowe N.J. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 3 (1988) 273-288
71. Stern R.S., Rosa F., and Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol 10 (1984) 851-854
72. Centers for Disease Control and Prevention (CDC). Accutane-exposed pregnancies-California, 1999. MMWR Morb Mortal Wkly Rep 49 (2000) 28-31
73. Charakida A., Mouser P.E., and Chu A.C. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf 3 (2004) 119-129
74. Landau M., Mesterman R., Ophir J., et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 81 (2001) 350-352
75. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 45 (2001) S188-S194
76. Goldsmith L.A., Bolognia J.L., Callen J.P., et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 50 (2004) 900-906
77. DiGiovanna J.J., Langman C.B., Tschen E.H., et al. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol 51 (2004) 709-717
78. Jacobs D.G., Deutsch N.L., and Brewer M. Suicide, depression, and isotretinoin: is there a causal link?. J Am Acad Dermatol 45 (2001) S168-S175
79. Jick S.S., Kremers H.M., and Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 136 (2000) 1231-1236
80. Marqueling A.L., and Zane L.T. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 26 (2007) 210-220
81. Feldman S.R. The moral of the isotretinoin depression story. J Dermatolog Treat 15 (2004) 199
82. Friedman T., Wohl Y., Knobler H.Y., et al. Increased use of mental health services related to isotretinoin treatment: a 5-year analysis. Eur Neuropsychopharmacol 16 (2006) 413-416
83. Hull P.R., and D'Arcy C. Acne, depression, and suicide. Dermatol Clin 23 (2005) 665-674
84. Hull P.R., and D'Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 4 (2003) 493-505
85. Enders S.J., and Enders J.M. Isotretinoin and psychiatric illness in adolescents and young adults. Ann Pharmacother 37 (2003) 1124-1127
86. Hendrix C.W., Jackson K.A., Whitmore E., et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 75 (2004) 464-475
87. Friedman D.I. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6 (2005) 29-37
88. Verros C.D., and Rallis E. Is oral isotretinoin the treatment of choice in moderate and severe inflammatory acne vulgaris?. J Eur Acad Dermatol Venereol 21 (2007) 1270-1271